STOCK TITAN

Precision Optics quarterly loss narrows to $475K

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Precision Optics Corporation, Inc. (POCI) reported revenue of $8,152,083 for the three months ended September 30, 2026, versus $6,680,823 a year earlier, a 22.0% increase. Gross profit was $1,837,851, compared with $946,358, and gross margin was 22.5% versus 14.2%. Net loss narrowed to $474,854 from $1,637,030; loss per share was $0.04 versus $0.21.

Operating activities used $672,145 in cash, compared with $78,227 provided in the prior-year quarter. Cash and equivalents were $8,966,889 at September 30, 2026, down from $9,841,142 at June 30, 2026. Management believes available cash, operating cash generation, line availability and the ability to raise capital will cover working capital and capital expenditures for at least 12 months, while stating that cash on hand and operating cash alone may be insufficient and short-term external financing may be required.

On September 25, 2026, Main Street Bank waived the debt-service coverage covenant for the fiscal year ended June 30, 2026, and replaced it with a $2.0 million minimum-liquidity covenant. POCI has access to $750,000 under the revolver, subject to borrowing-base requirements; availability may expand to $1,250,000 if it reaches a 1.2x debt-service coverage ratio. POCI reported compliance with the liquidity covenant at September 30, 2026.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • Moderate pointRevenue increased 22.0% to $8,152,083 year over year.
  • Moderate pointNet loss narrowed to $474,854 from $1,637,030.

Negative

  • Moderate pointOperating cash flow shifted to $672,145 used from $78,227 provided.

Filing Explained

The quarter added 21,638 issued shares, while 1,709,909 outstanding options remain potential rather than issued shares.

For the quarter ended September 30, 2026, Precision Optics issued 21,638 common shares for consulting services and employees, increasing shares outstanding from 10,972,792 at June 30 to 10,994,430; absent offsetting changes, this issuance reduces existing holders’ percentage ownership.

Separately, the company granted 50,000 options during the quarter; none were exercised, and 1,709,909 options remained outstanding at September 30, so those options are potential shares, not completed share issuance.

Revenue $8,152,083 Three months ended September 30, 2026; $6,680,823 in 2025, a 22.0% increase.
Gross profit $1,837,851 Three months ended September 30, 2026; $946,358 in 2025.
Gross margin 22.5% Three months ended September 30, 2026; 14.2% in 2025.
Net loss $474,854 loss Three months ended September 30, 2026; $1,637,030 loss in 2025.
Operating cash flow $672,145 used Three months ended September 30, 2026; $78,227 provided in 2025.
Cash and cash equivalents $8,966,889 At September 30, 2026; $9,841,142 at June 30, 2026.
Revolver availability $750,000 Access under modified credit arrangements, subject to borrowing-base requirements.
Minimum-liquidity covenant $2.0 million POCI reported compliance as of September 30, 2026.
minimum liquidity covenant financial
"minimum liquidity covenant of $2.0 million"
A minimum liquidity covenant is a clause in a loan or bond agreement that requires the borrower to keep a certain amount of cash or easily sold assets on hand, like an agreed emergency fund. It matters to investors because it protects lenders and other creditors by reducing the chance of missed payments; falling below the required level can trigger penalties, default, or demands for extra collateral, which can affect a company’s borrowing costs and equity value.
debt service coverage ratio financial
"minimum annual debt service coverage ratio covenant of 1.2x"
Debt service coverage ratio measures how many times a company's available cash flow can pay its scheduled debt payments (interest plus principal). Think of it like checking how many months of take-home pay it would take to cover your mortgage and loan bills; a higher number means a bigger cushion against missed payments. Investors use it to gauge credit risk, the likelihood of default, and whether a company can afford dividends or new borrowing.
contract liabilities financial
"The Company’s contract liabilities arise from unearned revenue"
Contract liabilities are amounts a company has been paid in advance for goods or services it still owes to customers — think of them like gift cards or prepaid subscriptions the company must fulfill later. For investors, they show promised future work or deliveries that will turn into revenue over time, reveal cash already collected, and help assess whether a firm has a backlog of obligations that could affect future earnings and cash flow.
right-of-use asset financial
"Operating lease right-of-use asset"
A right-of-use asset is the value a company records on its balance sheet for the practical use of something it leases — like the benefit of living in a rented office or using leased equipment for a set period. Investors care because it turns many leases into on-balance-sheet assets and matching liabilities, which can change reported leverage, asset base and performance metrics much like taking on a loan would.
bill and hold financial
"bill and hold contractual arrangements"
incurred but not reported financial
"claims incurred but not reported (IBNR)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was POCI's revenue for the quarter ended September 30, 2026?

POCI reported revenue of $8,152,083 for the three months ended September 30, 2026, compared with $6,680,823 in the same 2025 period.

How much operating cash did POCI use in the September 2026 quarter?

POCI used $672,145 in operating cash during the three months ended September 30, 2026, compared with $78,227 provided in the same period in 2025. Cash and equivalents were $8,966,889 at September 30, 2026.

What changed in POCI's credit agreement with Main Street Bank?

On September 25, 2026, the lender waived the debt-service coverage covenant for the fiscal year ended June 30, 2026, and replaced it with a $2.0 million minimum-liquidity covenant. POCI has access to $750,000 under the revolver, subject to borrowing-base requirements; availability can expand to $1,250,000 upon reaching a 1.2x debt-service coverage ratio.

Does POCI expect its liquidity to cover the next 12 months?

Management believes available cash and equivalents, cash generated from operations, line availability and the ability to raise funds will be sufficient for working capital and capital expenditures for at least 12 months. It also states that cash on hand and cash generated solely from operations may be insufficient, and short-term external financing may be required.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 2027 Q1 --06-30 0000867840 1 0000867840 2026-07-01 2026-09-30 0000867840 2026-11-12 0000867840 2026-09-30 0000867840 2026-06-30 0000867840 2025-07-01 2025-09-30 0000867840 us-gaap:CommonStockMember 2026-06-30 0000867840 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0000867840 us-gaap:RetainedEarningsMember 2026-06-30 0000867840 us-gaap:CommonStockMember 2025-06-30 0000867840 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000867840 us-gaap:RetainedEarningsMember 2025-06-30 0000867840 2025-06-30 0000867840 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0000867840 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0000867840 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0000867840 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0000867840 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0000867840 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0000867840 us-gaap:CommonStockMember 2026-09-30 0000867840 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0000867840 us-gaap:RetainedEarningsMember 2026-09-30 0000867840 us-gaap:CommonStockMember 2025-09-30 0000867840 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0000867840 us-gaap:RetainedEarningsMember 2025-09-30 0000867840 2025-09-30 0000867840 us-gaap:WarrantMember 2026-07-01 2026-09-30 0000867840 POCI:ReclassificationOfGovernmentReceivableMember 2025-07-01 2026-06-30 0000867840 POCI:ReclassificationOfGovernmentReceivableMember 2026-06-30 0000867840 POCI:IEEPATariffsPreviouslyPaidMember 2026-06-30 0000867840 POCI:IEEPATariffsPreviouslyPaidMember 2025-07-01 2026-06-30 0000867840 POCI:IEEPATarfiffRefundsMember 2026-06-30 0000867840 POCI:IEEPATarfiffRefundsMember 2025-07-01 2026-06-30 0000867840 2025-07-01 2026-06-30 0000867840 POCI:IEEPATariffRefundClaimsMember 2026-06-30 0000867840 POCI:IEEPATariffRefundClaimsMember 2026-09-30 0000867840 POCI:IEEPATariffSurchargesMember 2026-07-01 2026-09-30 0000867840 POCI:IEEPATarfiffRefundsMember 2026-09-30 0000867840 POCI:MainStreetTermLoanMember 2021-10-04 0000867840 POCI:MainStreetRevolverMember 2021-10-04 0000867840 POCI:MainStreetRevolverMember 2022-05-17 0000867840 POCI:MainStreetRevolverMember 2023-06-02 0000867840 POCI:MainStreetRevolverMember 2026-09-30 0000867840 POCI:MainStreetTermLoanMember 2026-07-01 2026-09-30 0000867840 POCI:MainStreetTermLoanMember 2026-09-30 0000867840 POCI:MainStreetBankWorkingCapitalLoanMember 2026-07-01 2026-09-30 0000867840 POCI:MainStreetBankWorkingCapitalLoanMember 2026-09-30 0000867840 POCI:ElPasoTexasMember 2026-09-30 0000867840 POCI:ElPasoTexasMember 2026-07-01 2026-09-30 0000867840 POCI:ElPasoTexasMember 2025-07-01 2025-09-30 0000867840 POCI:SouthPortlandMaineMember 2026-09-30 0000867840 POCI:SouthPortlandMaineMember 2026-07-01 2026-09-30 0000867840 POCI:SouthPortlandMaineMember 2025-07-01 2025-09-30 0000867840 POCI:LittletonMassachusettsMember 2026-09-30 0000867840 POCI:LittletonMassachusettsMember 2026-07-01 2026-09-30 0000867840 POCI:LittletonMassachusettsMember 2025-07-01 2025-09-30 0000867840 POCI:GardnerMassLeaseMember 2026-07-01 2026-09-30 0000867840 POCI:GardnerMassAdditionalFacilitiesMember 2026-07-01 2026-09-30 0000867840 POCI:GardnerMassAdditionalFacilitiesMember 2025-07-01 2025-09-30 0000867840 POCI:CostOfGoodsSoldMember 2026-07-01 2026-09-30 0000867840 POCI:CostOfGoodsSoldMember 2025-07-01 2025-09-30 0000867840 POCI:SellingGeneralAndAdministrativeExpenseMember 2026-07-01 2026-09-30 0000867840 POCI:SellingGeneralAndAdministrativeExpenseMember 2025-07-01 2025-09-30 0000867840 us-gaap:EmployeeStockOptionMember 2026-09-30 0000867840 POCI:March2026PublicOfferingMember 2026-03-30 0000867840 us-gaap:WarrantMember 2026-03-29 2026-03-30 0000867840 us-gaap:WarrantMember 2026-03-30 0000867840 us-gaap:WarrantMember 2026-09-30 0000867840 POCI:EngineeringDesignServicesMember 2026-07-01 2026-09-30 0000867840 POCI:EngineeringDesignServicesMember 2025-07-01 2025-09-30 0000867840 POCI:SystemsManufacturingMember 2026-07-01 2026-09-30 0000867840 POCI:SystemsManufacturingMember 2025-07-01 2025-09-30 0000867840 POCI:MicroOpticsLabMember 2026-07-01 2026-09-30 0000867840 POCI:MicroOpticsLabMember 2025-07-01 2025-09-30 0000867840 POCI:RossOpticalIndustriesMember 2026-07-01 2026-09-30 0000867840 POCI:RossOpticalIndustriesMember 2025-07-01 2025-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure POCI:Integer

Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

or

 

☐  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                      to                     

 

Commission File Number: 001-10647

 

PRECISION OPTICS CORPORATION, INC.

(Exact name of registrant as specified in its charter)

 

Massachusetts 04-2795294
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

 

550 King Street, Bldg. A, Ste. 100,

Littleton, Massachusetts 01460-6245

(Address of principal executive offices) (Zip Code)

 

(978) 630-1800

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act: 

 

Title of each class Trading symbol(s) Name of each exchange on which registered
Common Stock, $0.01 par value POCI Nasdaq

 

Securities registered pursuant to Section 12(g) of the Act: None.

  

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

   

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer ☐   Accelerated filer ☐  
  Non-accelerated filer ☒   Smaller reporting company ☒  
        Emerging growth company ☐  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The number of shares outstanding of the issuer’s common stock, par value $0.01 per share, at November 12, 2026 was 10,994,430 shares.

 

 

   

 


PRECISION OPTICS CORPORATION, INC.

 

Table of Contents

 

  Page
   
PART I FINANCIAL INFORMATION 3
Item 1. Financial Statements 3
Balance Sheets at September 30, 2026 and June 30, 2026 3
Statements of Operations for the Three Months Ended September 30, 2026 and 2025 4
Statements of Stockholders’ Equity for the Three Months Ended September 30, 2026 and 2025 5
Statements of Cash Flows for the Three Months Ended September 30, 2026 and 2025 6
Notes to Financial Statements 7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 17
Item 3. Quantitative and Qualitative Disclosures About Market Risk 21
Item 4. Controls and Procedures 21
   
PART II OTHER INFORMATION 22
Item 1. Legal Proceedings 22
Item 1A. Risk Factors 22
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22
Item 3. Defaults Upon Senior Securities 22
Item 4. Mine Safety Disclosures (Not applicable) 22
Item 5. Other Information 22
Item 6. Exhibits 23

 

 

 

 

 

 2 

 

 

PART I. FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

PRECISION OPTICS CORPORATION, INC.

BALANCE SHEETS

(UNAUDITED)

         
   September 30,   June 30, 
   2026   2026 
ASSETS          
Current Assets:          
Cash and cash equivalents  $8,966,889   $9,841,142 
Accounts receivable, net of allowance for credit losses of $109,055 at September 30, 2026 and $108,220 at June 30, 2026   5,371,290    5,944,412 
Inventories, net   3,518,893    3,829,414 
Prepaid expenses   586,022    494,488 
Total current assets   18,443,094    20,109,456 
           
Fixed Assets:          
Machinery and equipment   3,427,461    3,410,813 
Leasehold improvements   1,226,171    1,226,171 
Furniture and fixtures   674,445    645,046 
Total fixed assets   5,328,077    5,282,030 
Less—accumulated depreciation and amortization   4,415,080    4,394,317 
Net fixed assets   912,997    887,713 
           
Operating lease right-of-use asset   2,229,155    2,300,866 
Patents, net   206,597    212,889 
Goodwill   8,824,210    8,824,210 
Total other assets   11,259,962    11,337,965 
TOTAL ASSETS  $30,616,053   $32,335,134 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current Liabilities:          
Current maturities of long-term debt  $577,898   $577,898 
Accounts payable   2,620,358    3,582,674 
Customer advances   2,342,890    2,498,501 
Accrued compensation and other   1,619,014    1,843,368 
Current portion of operating lease liability   335,011    325,500 
Total current liabilities   7,495,171    8,827,941 
           
Long-term debt, net of current maturities   562,023    711,305 
Operating lease liability, net of current portion   2,358,873    2,446,576 
Total liabilities   10,416,067    11,985,822 
           
Stockholders’ Equity:          
Common stock, $0.01 par value: 50,000,000 shares authorized; issued and outstanding – 10,994,430 shares at September 30, 2026 and 10,972,792 at June 30, 2026   109,944    109,728 
Additional paid-in capital   81,165,417    80,840,105 
Accumulated deficit   (61,075,375)   (60,600,521)
Total stockholders’ equity   20,199,986    20,349,312 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $30,616,053   $32,335,134 

 

The accompanying notes are an integral part of these interim financial statements.

 

 

 3 

 

 

PRECISION OPTICS CORPORATION, INC.

STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS ENDED

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

         
   Three Months
Ended September 30,
 
   2026   2025 
Revenues  $8,152,083   $6,680,823 
           
Cost of Goods Sold   6,314,232    5,734,465 
Gross Profit   1,837,851    946,358 
           
Research and Development Expenses   306,215    311,840 
Selling, General and Administrative Expenses   2,049,946    2,229,773 
Total Operating Expenses   2,356,161    2,541,613 
           
Operating Loss   (518,310)   (1,595,255)
           
Other income (expense):          
Interest expense   (30,121)   (41,775)
Interest income   73,577    – 
           
Net Loss  $(474,854)  $(1,637,030)
           
Loss Per Share:          
Basic & Fully Diluted  $(0.04)  $(0.21)
           
Weighted Average Common Shares Outstanding:          
Basic & Fully Diluted   10,974,771    7,714,701 

 

The accompanying notes are an integral part of these interim financial statements.

 

 

 

 

 4 

 

 

PRECISION OPTICS CORPORATION, INC.

STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE THREE MONTHS ENDED

sEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

                     
   Three Month Period Ended September 30, 2026 
   Number of
Shares
   Common
Stock
   Additional
Paid-in
Capital
   Accumulated
Deficit
   Total
Stockholders’
Equity
 
                     
Balance, July 1, 2026   10,972,792   $109,728   $80,840,105   $(60,600,521)  $20,349,312 
Issuance of common stock for consulting services and employees   21,638    216    96,034    –    96,250 
Stock-based compensation   –    –    229,278    –    229,278 
Net loss   –    –    –    (474,854)   (474,854)
Balance, September 30, 2026   10,994,430   $109,944   $81,165,417   $(61,075,375)  $20,199,986 

 

                     
   Three Month Period Ended September 30, 2025 
   Number of
Shares
   Common
Stock
   Additional
Paid-in
Capital
   Accumulated
Deficit
   Total
Stockholders’
Equity
 
                     
Balance, July 1, 2025   7,714,701   $77,147   $69,152,317   $(56,970,630)  $12,258,834 
Stock-based compensation   –    –    301,639    –    301,639 
Net loss   –    –    –    (1,637,030)   (1,637,030)
Balance, September 30, 2025   7,714,701   $77,147   $69,453,956   $(58,607,660)  $10,923,443 

 

The accompanying notes are an integral part of these interim financial statements.

 

 

 

 

 5 

 

 

PRECISION OPTICS CORPORATION, INC.

STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED

September 30, 2026 AND 2025

(UNAUDITED)

         
   Three Months
Ended September 30,
 
   2026   2025 
Cash Flows from Operating Activities:          
Net Loss  $(474,854)  $(1,637,030)
Adjustments to reconcile net loss to net cash used in operating activities -          
Depreciation and amortization   65,271    65,181 
Stock-based compensation expense   235,528    301,639 
Non-cash interest expense   4,801    4,608 
Non-cash operating lease expense   (6,481)   49,322 
(Gain) Loss on disposal of fixed assets   (36,238)   34,506 
Changes in operating assets and liabilities -          
Accounts receivable, net   573,122    148,797 
Inventories, net   310,521    (318,196)
Prepaid expenses   (91,534)   (14,240)
Accounts payable   (962,316)   1,099,235 
Contract liabilities   (155,611)   208,843 
Accrued compensation and other   (134,354)   135,562 
Net cash provided by (used in) operating activities   (672,145)   78,227 
           
Cash Flows from Investing Activities:          
Purchases of fixed assets   (84,263)   (304,731)
Proceeds from sale of fixed assets   36,238    3,000 
Additional patent costs   –    (58)
Net cash used in investing activities   (48,025)   (301,789)
           
Cash Flows from Financing Activities:          
Payments of capital lease obligations   –    (8,985)
Payments of debt issuance costs   (5,000)   – 
Payments of long-term debt   (149,083)   (149,083)
Net cash used in financing activities   (154,083)   (158,068)
           
Net decrease in cash and cash equivalents   (874,253)   (381,630)
Cash and cash equivalents, beginning of period   9,841,142    1,773,735 
           
Cash and cash equivalents, end of period  $8,966,889   $1,392,105 
           
Supplemental disclosure of cash flow information:          
Cash paid during the period for income taxes  $–   $2,600 
Cash paid during the period for interest  $25,320   $37,167 
Issuance of common stock for employee services  $96,250   $– 
Operating right-of-use assets obtained in exchange for operating lease liabilities  $–   $2,632,584 
Lease improvements financed by landlord  $–   $218,750 

 

The accompanying notes are an integral part of these interim financial statements.

 

 

 6 

 

 

PRECISION OPTICS CORPORATION, INC.

NOTES TO INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

 

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Principles of Consolidation and Operations

 

These financial statements have been prepared by the Company, without audit, and reflect normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the results of the first three months of the Company’s fiscal year 2027. These financial statements do not include all disclosures associated with annual financial statements and, accordingly, should be read in conjunction with footnotes contained in the Company’s audited financial statements for the year ended June 30, 2026, together with the Report of Independent Registered Public Accounting Firm filed under cover of the Company’s 2026 Annual Report on Form 10-K, filed with the Securities and Exchange Commission on September 28, 2026.

 

Use of Estimates

 

The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

 

Income (Loss) Per Share

 

Basic income (loss) per share is computed by dividing net income or net loss by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period, plus the number of potentially dilutive securities outstanding during the period such as stock options and warrants. For the three months ended September 30, 2026 and 2025, potentially dilutive securities outstanding have been excluded from the computations of weighted-average shares outstanding because such securities have an antidilutive impact due to the net loss reported during those periods. The number of shares issuable upon the exercise of outstanding stock options that were excluded from the computation of fully diluted weighted average shares outstanding was 1,709,909 for the three months ended September 30, 2026 and 1,623,576 for the three months ended September 30, 2025. In addition, 159,722 shares issuable upon exercise of outstanding warrants were excluded for the three months ended September 30, 2026.

 

The following is the calculation of income (loss) per share for the three months ended September 30, 2026 and 2025:

        
   Three Months
Ended September 30,
 
   2026   2025 
Net Income (Loss) Basic and Fully Diluted  $(474,854)  $(1,637,030)
           
Weighted Average Shares Outstanding          
Basic & Fully Diluted   10,974,771    7,714,701 
           
Loss Per Share – Basic & Fully Diluted  $(0.04)  $(0.21)

 

 

 

 7 

 

 

Significant Customers and Concentration of Credit Risk

 

Financial instruments that subject the Company to credit risk consist primarily of cash equivalents and trade accounts receivable. The Company places its investments with highly rated financial institutions. The Company has not experienced any losses on these investments to date.

 

The allowance for credit losses was $109,055 at September 30, 2026, and $63,804 at September 30, 2025.

        
   Three Months Ended September 30, 
   2026   2025 
Allowance for credit losses, beginning of period  $108,220   $80,192 
Change in the provision for expected credit losses   835    (16,388)
Allowance for credit losses, end of period  $109,055   $63,804 

 

During the three months ended September 30, 2026, the Company increased the credit loss reserve. Management believes the allowance for credit losses, which is established based upon review of specific account balances and historical experience, is adequate at September 30, 2026.

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

  

In assessing the likelihood of utilization of existing deferred tax assets, management has considered the historical results of operations and the current operating environment. Based on this evaluation, a full valuation allowance has been provided for the deferred tax assets.

 

Segment Reporting

 

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions about how to allocate resources and assess performance. The Company’s chief operating decision maker is its Chief Executive Officer. To date, the Company has viewed its operations and manages its business as principally one segment. The chief operating decision maker assesses performance for the single reporting segment and decides how to allocate resources based on revenues, gross profit, and net income (loss) that also is reported on the income statement as revenues, gross profit, and net income (loss). The measure of segment assets is reported on the balance sheet as total assets.

 

Recent Accounting Pronouncements

 

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires additional disclosures about certain expenses included in the expense captions presented on the statement of operations. The guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting this guidance on its financial statement disclosures.

 

 

 

 8 

 

 

Government Grants

 

The Company accounts for government grants in accordance with ASC 832, Government Grants, as amended by ASU 2025-10, which the Company early adopted during the year ended June 30, 2026. The Company recognizes grants or subsidies from governments as a receivable when it is probable that the Company will comply with any conditions associated with the grant arrangement and the grant will be received. The Company evaluates the conditions of each grant as of each reporting period to determine whether it is probable that the Company has met the conditions of each grant arrangement. Grants are recognized in the statements of operations on a systematic basis over the periods in which the Company recognized the related costs for which the grant is intended to compensate. The Company records grant receivables in the balance sheets in accounts receivable, depending on when the amounts are expected to be received from the government agency.

 

During the year ended June 30, 2026, the Company recognized a reduction to expense of $224,544 related to grants within the statements of operations, all in cost of goods sold. For the three months ended September 30, 2026, the Company has $224,544 recorded as a government receivable, included in accounts receivable, which relates to personnel, direct costs and operating expenses to be reimbursed and received as cash. As of June 30, 2026, the Company had $224,544 government receivable.

 

Derivative Financial Instruments

 

The Company evaluates warrants and other financial instruments to determine whether such instruments or embedded features qualify as derivatives to be accounted for separately in accordance with ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging. Warrants that do not meet the criteria for equity classification are recorded as liabilities at fair value and are remeasured at each reporting date until exercised, expired, modified, or otherwise settled. Changes in the fair value of warrant liabilities are recognized in other income (expense), net in the statements of operations.

 

Warrants that meet the criteria for equity classification, including the scope exception under ASC 815-10-15-74(a), are classified within stockholders’ equity and are not subsequently remeasured as long as the conditions for equity classification continue to be met.

 

The Company reassesses the classification of warrants at each reporting date. As of September 30, 2026, the Company determined that all outstanding warrants qualified for equity classification.

 

IEEPA Tariff Refunds and Related Customer Refunds

 

On February 20, 2026, the U.S. Supreme Court issued a ruling relating to tariffs imposed under the International Emergency Economic Powers Act (“IEEPA”). Following the ruling, U.S. Customs and Border Protection and other federal agencies issued additional guidance and took actions affecting the assessment, collection, refund, and/or protest of certain tariffs. In March 2026, the U.S. Court of International Trade issued an additional ruling stating that importers that have paid tariffs under IEEPA are due refunds.

 

Accordingly, during the year ended June 30, 2026, the Company recorded a receivable of $880,598 within accounts receivable in the balance sheet, representing recovery of IEEPA tariffs previously paid, with a corresponding offset to cost of goods sold. In addition, the Company recorded a $558,266 liability within accrued compensation and other in the balance sheet as a result of its decision to refund IEEPA tariff surcharges collected from customers, with a corresponding reduction of revenue in the statement of operations. In the year ended June 30, 2026, we received $37,576 in IEEPA tariff refund proceeds, resulting in outstanding IEEPA tariff refund claims receivable of $843,022 within “accounts receivable” in the balance sheet, representing a recovery of IEEPA tariffs previously paid.

 

During the three months ended September 30, 2026, the Company received IEEPA tariff refund proceeds, excluding interest, of $236,286 reducing the outstanding receivable to $606,736 at September 30, 2026. During the same period, the Company refunded $190,117 of IEEPA tariff surcharges to customers, reducing the remaining liability within accrued compensation and other to $368,149 at September 30, 2026.

 

 

 

 9 

 

 

Goodwill and Patents

 

Long-lived assets such as goodwill and patents are capitalized when acquired and reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Impairment of the carrying value of long-lived assets such as goodwill and patents would be indicated if the best estimate of future undiscounted cash flows expected to be generated by the asset grouping is less than its carrying value. If an impairment is indicated, any loss is measured as the difference between estimated fair value and carrying value and is recognized in operating income or loss. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No such impairments of goodwill or patents have been estimated by management as of September 30, 2026. Amortization expense for the three months ended September 30, 2026 and 2025 was $6,292 and $6,292, respectively.

 

 

2. INVENTORIES

 

Inventories are stated at the lower of cost (first-in, first-out) or market and consisted of the following:

        
   September 30,
2026
   June 30,
2026
 
Raw Materials  $1,796,915   $2,043,446 
Work-In-Progress   537,739    570,360 
Finished Goods   1,184,239    1,215,608 
Total Inventories  $3,518,893   $3,829,414 

 

 

3. BANK FINANCING ACTIVITIES

 

Bank Term Loan and Line of Credit

 

On October 4, 2021, the Company entered into a Loan Agreement with Main Street Bank of Marlborough, Massachusetts (the “Lender”), which provided for a $2,600,000 Term Loan and a $250,000 Revolving Line of Credit Loan Facility (the “Revolver”), which was increased to $500,000 effective May 17, 2022, and $1,250,000 effective June 2, 2023. Borrowings under the Revolver are limited by the borrowing base comprised of a percentage of accounts receivable and inventory and secured by all assets of the Company. Borrowings under the Revolver bear interest payable monthly at the prime lending rate plus 1.5% per annum and shall not be less than 4.75% per annum. Borrowings under the Revolver are due upon demand. There were no borrowings under the Revolver at September 30, 2026.

  

The Company’s Loan Agreement with the Lender contains a minimum annual debt service coverage ratio covenant of 1.2x. The Company did not meet this annual debt service coverage ratio for the fiscal year ended June 30, 2024. The Company’s Lender agreed to waive compliance with such debt service coverage ratio covenant for the period ended June 30, 2024. In addition to such waiver, the Lender and the Company entered into an amendment dated September 30, 2024 to that certain Term Loan dated October 4, 2021, as amended and that certain Promissory Note dated June 2, 2023 (collectively, the “Notes”) which amendments provided for a six-month period of interest only payments from October 15, 2024 through March 15, 2025 for the Notes. The Company commenced payments of principal and interest under the Notes beginning with the payments due on April 15, 2025, with a new amortization schedule for the remaining term for such Notes through their maturity date. On February 14, 2025, the Lender agreed to waive compliance with the annual debt service coverage ratio covenant for the fiscal year ending June 30, 2025, subject to a $30,000 waiver fee and the completion of an equity raise of at least $4,500,000 by February 24, 2025, which the Company satisfied on February 21, 2025.

 

 

 

 10 

 

 

On September 25, 2026, the Lender agreed to waive the Company’s minimum annual debt service coverage ratio covenant for the fiscal year ended June 30, 2026 and modified the Company’s credit arrangements to eliminate the debt service coverage ratio covenant and replace it with a minimum liquidity covenant of $2.0 million, retain the existing term note, and provide the Company access to $750,000 of availability under the Revolver, subject to borrowing-base requirements and a $5,000 waiver fee. The Lender further agreed to expand availability under the Revolver to $1,250,000 upon the Company attaining a debt service coverage ratio of 1.2x. There were no other changes or modifications to the Loan Agreement or the Notes. The Company was in compliance with the minimum liquidity covenant as of September 30, 2026.

 

Long-Term Debt

 

Long-term debt consists of the following at September 30, 2026 and June 30, 2026:

        
   September 30,
2026
   June 30,
2026
 
Term Loan Note payable to Main Street Bank with monthly principal payments of $35,271, excluding six months in Fiscal 2025, plus interest at a fixed rate of 7.0% per annum. Secured by all assets of the Company, and subject to certain periodic reporting to the bank and other conditions including an annual minimum EBITDA plus stock-based compensation to debt service coverage ratio of 1.20:1 commencing with the fiscal year ending June 30, 2023. The Term Loan Note matures on October 15, 2028.  $881,783   $987,597 
           
Permanent Working Capital Loan payable to Main Street Bank with monthly principal payments of $14,423, excluding six months in Fiscal 2025, plus interest at a fixed rate of 8.625% per annum. Secured by all assets of the Company, and subject to certain periodic reporting to the bank and other conditions including an annual minimum EBITDA plus stock-based compensation to debt service coverage ratio of 1.20:1 commencing with the fiscal year ending June 30, 2023. The Permanent Working Capital Loan matures on June 15, 2028.   302,885    346,154 
           
Less current maturities   (577,898)   (577,898)
Less debt issuance costs, net of accumulated amortization of $47,988 and $34,364, respectively.   (44,747)   (44,548)
Long-term debt, net of current maturities and debt issuance costs  $562,023   $711,305 

 

At September 30, 2026 principal payments due on long-term debt are as follows:

    
Fiscal Year Ending June 30:    
2027  $447,250 
2028   596,333 
2029   141,085 
Total long-term debt  $1,184,668 

 

 

 

 

 11 

 

 

4. LEASE OBLIGATIONS

 

On July 1, 2019 the Company entered into a three-year operating lease for its facility in El Paso, Texas, and in February 2022 the Company entered into an extension of the lease for an additional three years through June 2025. In May 2025, this lease was extended for an additional three years through May 2028. Remaining minimum lease payments at September 30, 2026 total $86,013. Total lease costs including base rent and common area expenses were $18,397 and $20,052 during the three months ended September 30, 2026 and 2025, respectively. The amount of variable lease payments is immaterial. Included in the accompanying balance sheet at September 30, 2026 is a right-of-use asset of $78,655 and current and long-term operating lease liabilities of $44,284 and $33,918, respectively. The applicable discount rate utilized for this lease at commencement was 9.0%.

 

On May 14, 2025 the Company entered into a seven-year lease in South Portland, Maine with two five-year extension options. The extension options have been accounted for under the assumption that they will not be exercised. Remaining minimum lease payments at September 30, 2026 total $1,013,294. Total lease costs including base rent and common area expenses were $48,664 and $32,661 during the three months ended September 30, 2026 and 2025, respectively. The amount of variable lease payments is immaterial. Included in the accompanying balance sheet at September 30, 2026 is a right-of-use asset of $510,772 and current and long-term operating lease liabilities of $71,385 and $679,564, respectively. The applicable discount rate utilized for this lease at commencement was 9.0%.

 

On June 2, 2025 the Company entered into a seven-year operating lease in Littleton, Massachusetts with two five-year extension options. The extension options have been accounted for under the assumption that they will not be exercised. Remaining minimum lease payments at September 30, 2026 total $2,408,003. Total lease costs including base rent and common area expenses were $141,027 and $30,456 during the three months ended September 30, 2026 and 2025, respectively. The amount of variable lease payments is immaterial. Included in the accompanying balance sheet at September 30, 2026 is a right-of-use asset of $1,639,728 and current and long-term operating lease liabilities of $219,342 and $1,645,391, respectively. The applicable discount rate utilized for this lease at commencement was 9.0%.

 

On October 28, 2026 the Company entered into a one-year operating lease in Gardner, Massachusetts with two one-year extension options. The extension options have been accounted for under the assumption that they will not be exercised. The rent commencement date of the lease was July 1, 2026. Total lease costs were $39,949 during the three months ended September 30, 2026.

 

The weighted average discount rate is 9.0% at September 30, 2026 and 9.0% at September 30, 2025. The weighted average lease term is 6.1 years at September 30, 2026 and 7.1 years at September 30, 2025. As the rates implicit in the Company’s leases are generally not readily determinable, the Company utilizes its incremental borrowing rate to determine the present value of lease payments. The incremental borrowing rate represents the interest rate the Company would be required to pay to borrow on a collateralized basis over a similar term in an amount equal to the lease payments. The Company estimates the incremental borrowing rate using information available at the lease commencement date, including prevailing market interest rates, the Company’s credit profile, and the term of the lease. In circumstances where the implicit rate is readily determinable, that rate is used instead of the incremental borrowing rate.

 

 

 

 

 12 

 

 

At September 30, 2026 future minimum lease payments under the operating lease obligations are as follows:

    
Fiscal Year Ending June 30:  Operating Lease 
2027  $418,696 
2028   567,327 
2029   535,107 
2030   551,240 
2031   567,784 
Thereafter   867,155 
Total Minimum Payments   3,507,309 
Less: amount representing interest   813,425 
Present value of minimum lease payments   2,693,884 
Less: current portion   335,011 
Future minimum long-term lease liability  $2,358,873 

 

The Company rents additional facilities in Gardner, Massachusetts, for production and storage, primarily on a tenant-at-will basis. Rent expense on these operating leases was $50,631 and $57,884 for the three months ended September 30, 2026 and 2025, respectively

 

 

5. STOCK-BASED COMPENSATION

 

Stock Options

 

The following table summarizes stock-based compensation expense for the three months ended September 30, 2026 and 2025.

        
   Three Months
Ended September 30,
 
   2026   2025 
Cost of Goods Sold  $28,626   $31,069 
Selling, General and Administrative   206,902    270,570 
Stock Based Compensation Expense  $235,528   $301,639 

 

No compensation has been capitalized because such amounts would have been immaterial.

 

 

 

 

 13 

 

 

The following tables summarize stock option activity for the three months ended September 30, 2026:

             
   Options Outstanding 
   Number of
Shares
   Weighted Average
Exercise Price
   Weighted Average
Contractual Life
 
Outstanding at June 30, 2026   1,659,909   $4.82    6.65 years 
Grants   50,000    4.34    9.88 years 
Exercised   –    –    – 
Cancelled, forfeited, or expired   –    –    – 
Outstanding at September 30, 2026   1,709,909   $4.81    6.50 years 

  

The aggregate intrinsic value of the Company’s in-the-money outstanding and exercisable options as of September 30, 2026 was $346,497.

 

 

6. STOCK WARRANTS

 

In connection with the public offering that closed on March 30, 2026, the Company issued to the underwriter warrants to purchase 159,722 shares of common stock at an exercise price of $4.21 per share. The warrants are immediately exercisable and expire on March 27, 2031. Each warrant is exercisable for one share of common stock.

 

The warrants were classified as equity instruments under ASC 815-40, as the warrants are indexed to the Company's own common stock and may be settled in shares at the Company's option without any obligation to net cash settle under any circumstances.

 

The fair value of the warrants on the issuance date of March 30, 2026 was approximately $342,687, determined using a Black-Scholes option pricing model with the following assumptions: stock price $4.20, exercise price $4.21, expected term of approximately 5 years, expected volatility of 54.8%, risk-free interest rate of 3.9%, and dividend yield of 0%. The fair value was recorded as an additional issuance cost and recognized as a reduction to additional paid-in capital, with an offsetting credit to additional paid-in capital — warrants outstanding. The net impact on total stockholders' equity was zero.

 

As of September 30, 2026, all 159,722 warrants remain outstanding and unexercised.

 

 

7. CAPTIVE INSURANCE AND SELF-INSURED RISKS

 

Effective June 1, 2026, the Company established a self-funded employee health insurance program and began participating in a group captive insurance arrangement. Under the program, the Company is responsible for eligible employee healthcare claims, subject to stop-loss insurance coverage designed to limit exposure to significant individual and aggregate claims.

 

The Company recognizes the cost of healthcare claims in the period in which the underlying services are incurred, including an estimate for claims incurred but not reported (“IBNR”). The estimated liability is based on available claims information, historical healthcare costs and other relevant information available to management. Estimates are subject to uncertainty, and actual claims may differ from amounts estimated and recorded.

 

At September 30, 2026, the Company’s accrued liability for healthcare claims, including IBNR, was approximately $90,000.

 

 

 

 14 

 

 

8. REVENUE RECOGNITION

 

The Company determines revenue recognition for arrangements that it determines are within the scope of Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers,” or ASC 606, by performing the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the Company satisfies the performance obligations. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract determines those that are performance obligations and assesses whether each promised good or service is distinct based on the contract.

 

The Company disaggregates revenues by product and service types as it believes best depicts how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors. Revenues are comprised of the following for the three months ended September 30, 2026 and 2025:

        
   Three Months
Ended September 30,
 
   2026   2025 
Engineering Design Services  $728,466   $656,101 
Systems Manufacturing   5,785,153    4,866,706 
Micro-Optics Lab   305,806    100,376 
Ross Optical Industries   1,332,658    1,057,640 
Total Revenues  $8,152,083   $6,680,823 

 

Selling costs to obtain and fulfill contracts are expensed as incurred due to the short-term nature of a majority of contracts. The Company extends terms of payment to its customers based on commercially reasonable terms for the markets of its customers, while also considering their credit quality. Shipping and handling costs charged to customers are included in revenue.

 

Revenue recognition policies for each of the four product and service types appear below.

 

Engineering Design Services

 

The Company enters into contractual agreements with its customers, including design services agreements, and statements of work and receives purchase orders for development projects. These agreements provide costs on an estimated basis for the services the Company has agreed to provide. Engineering Design Services are rendered on a time and materials basis. The Company recognizes revenue as customers are invoiced for the actual engineering services provided in the period. Revenue is also recognized on materials purchased for development projects at the time of receipt. Engineering Design Services are provided on a best-efforts basis; no warranty is provided as there is no guarantee that the work will result in the attainment of the customer’s project objectives. The Company may obtain customer deposits in advance of rendering engineering design services. Customer deposits are treated as contract liabilities until the terms of customer agreements are satisfied and are not a component of revenue.

 

 

 

 

 15 

 

 

Systems Manufacturing, Micro-Optics Laboratory, Ross Optical Industries

 

The Company provides fixed price quotations to its customers and requires purchase orders for items manufactured and distributed through the Systems Manufacturing, Micro-Optics Laboratory and Ross Optical Industries business units. Revenue is recognized at the time title passes to the customer based on the Company’s review of the customer contract, generally at the time of shipment from the Company’s facilities. Occasionally the Company may enter into “bill and hold” contractual arrangements where title is held by its customers while goods are stored at the Company’s facilities for the customer’s convenience.

 

Contract Assets and Liabilities

 

The nature of the Company’s products and services does not generally give rise to contract assets as it typically does not incur costs to fulfill a contract before a product or service is provided to a customer. The Company’s costs to obtain contracts are typically in the form of sales commissions paid to employees. The Company has elected to expense sales commissions associated with obtaining a contract as incurred as the amortization period is generally less than one year. These costs have been recorded in selling, general and administrative expenses. As of September 30, 2026, there were no contract assets recorded in the Company’s Balance Sheets.

  

The Company’s contract liabilities arise from unearned revenue received from customers at inception of contracts or where the timing of billing for services precedes satisfaction of our performance obligations. The Company generally satisfies performance obligations within one year from the contract’s inception date.

  

Contract liabilities, which are recorded in the Company’s Balance Sheets, and unearned revenue are comprised of the following:

        
   Three Months
Ended September 30,
 
   2026   2025 
Contract liabilities, beginning of period  $2,498,501   $1,821,929 
Unearned revenue received from customers   719,233    1,130,915 
Revenue recognized   (874,844)   (922,072)
Contract liabilities, end of period  $2,342,890   $2,030,772 

 

 

 

 

 

 16 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion of our financial condition and results of operations should be read in conjunction with the unaudited condensed financial statements and notes to those statements included elsewhere in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and with our audited financial statements for the year ended June 30, 2026 included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on September 28, 2026.

 

This Quarterly Report on Form 10-Q contains forward-looking statements. When used in this report, the words "anticipate," "suggest," "estimate," "plan," "project," "continue," "ongoing," "potential," "expect," "predict," "believe," "intend," "may," "will," "should," "could," "would" and similar expressions are intended to identify forward-looking statements. You should not place undue reliance on these forward-looking statements. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons, including the risks described in this report, the risks described in our Annual Report on Form 10-K for the year ended June 30, 2026 and other reports we file with the Securities and Exchange Commission. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made. We do not intend to update any of the forward-looking statements after the date of this report to conform these statements to actual results or to changes in our expectations, except as required by law.

 

Overview

 

We have been a developer and manufacturer of advanced optical instruments since 1982, and we operate primarily in two key market segments: medical devices and advanced defense/aerospace products. Within our proprietary optical and imaging technology, our unique custom designs, expert manufacturing capabilities, and advanced engineering and development capabilities have generated traditional endoscopes and endocouplers, digital imaging endoscopes using CMOS sensor technology, some designed and manufactured for single-use, as well as other, more advanced, custom imaging and illumination products for our customers’ use in minimally invasive surgical procedures. We design and manufacture ultra-high precision endoscopes and very small Microprecision lenses, assemblies and complete medical devices to meet the surgical community’s continuing demand for smaller, disposable, and more enhanced imaging systems for minimally invasive surgery. We also apply our unique technologies to applications in the Defense / Aerospace markets including applications supporting satellite network communications.

 

To support these two critical market categories, our business operations are conducted in four areas: systems manufacturing, engineering and product development, Ross Optical components and assemblies, and our micro-optics laboratory. Our systems manufacturing operations assemble and manufacture components and systems for both medical device and advanced aerospace customers who choose to outsource these services based on our ability to handle high complexity components, specific optical technologies, micro-optical assemblies and other advanced manufacturing challenges. Our engineering and product development team assesses specific customer product needs, designs devices to solve those needs, and creates manufacturing processes that enable higher volume production of these devices and assemblies that can then be executed by our manufacturing operations group.

 

Effective June 1, 2019, we acquired the operating assets of Ross Optical Industries, Inc. of El Paso, Texas. This acquisition expanded our optics components and assemblies’ business. As Ross Optical Industries, we operate as a supplier of custom optical components and assemblies for military and defense, medical and various other industrial applications. All products sold by us under the Ross Optical name include a custom or catalog optic, which is sourced through our extensive domestic and worldwide network of optical fabrication suppliers. Most systems make use of optical lenses, prisms, mirrors and windows and range from individual optical components to complex mechano-optical assemblies. Products often include thin film optical coatings applied using our in-house coating department.

 

Effective October 1, 2021, we acquired the operating assets of Lighthouse Imaging, LLC of Windham, Maine, which expanded our electrical engineering capabilities in the development of end-to-end medical visualization devices. The acquisition represented a vertical integration of our established product development capabilities with a team with extensive experience developing visualization systems that we believe provide our customers with single-source value-added development services and product offerings. The operations of Lighthouse Imaging have been integrated with other operations of the company, which continue under the POC brand, so that the company now operates with single systems manufacturing and engineering departments, each of which includes historical POC and Lighthouse Imaging resources.

 

 

 

 17 

 

 

General

 

This management’s discussion and analysis of financial condition and results of operations is based upon our unaudited financial statements, which have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material.

 

Critical Accounting Policies and Estimates

 

There have been no significant changes in our critical accounting policies as disclosed in the Notes to our Financial Statements contained in our Annual Report on Form 10-K for the year ended June 30, 2026 filed with the Securities and Exchange Commission on September 28, 2026.

 

Results of Operations

 

Revenue

 

  

Three Months

Ended September 30,

 
   2026  

Percent

of Sales

   2025  

Percent

of Sales

  

Increase

(Decrease)

  

Percent

Change

 
Engineering Design Services   728,466    8.9    656,101    9.8    72,365    11.0 
Systems Manufacturing   5,785,153    71.0    4,866,706    72.9    918,447    18.9 
MicroOptics Lab   305,806    3.8    100,376    1.5    205,430    204.7 
Ross Optical Industries   1,332,658    16.3    1,057,640    15.8    275,018    26.0 
Total Revenues   8,152,083    100.0    6,680,823    100.0    1,471,260    22.0 

 

Total revenues for the quarter ended September 30, 2026 were $8,152,083, as compared to $6,680,823 for the same period in the prior year, an increase of $1,471,260. Revenue from Engineering Design Services increased 11.0% during the quarter ended September 30, 2026 from the prior year period ended September 30, 2025. During the quarter ended September 30, 2026 revenue increases in the engineering category resulted from improving utilization.

 

Revenue from Systems Manufacturing increased 18.9% during the quarter ended September 30, 2026 from the same period in the prior year, due primarily to significant increases in customer demand and the resultant scaling of manufacturing capabilities.

 

Revenue from the MicroOptics Lab increased over 200% during the quarter ended September 30, 2026 from the same period in the prior year, and included new orders from our defense customer.

 

Revenue from Ross Optical Industries increased 26.0% during the quarter ended September 30, 2026 from the same period in the prior year, which we believe was due to a reduction in tariff uncertainty.

 

 

 

 18 

 

 

Gross Profit

 

Gross margin increased to 22.5% during the quarter ended September 30, 2026, compared to 14.2% for the quarter ended September 30, 2025. Gross profit increased to $1,837,851 during the three months ended September 30, 2026, compared to $946,358 for the three months ended September 30, 2025. The primary factors for the increase in gross profit include higher revenue levels for Ross Optical and the MicroOptics Laboratory, higher revenue and improved yields for manufacturing lines, and increases in royalties.

 

Research & Development

 

R&D expenses decreased $5,625 to $306,215 during the quarter ended September 30, 2026, compared to $311,840 during the quarter ended September 30, 2025. R&D expenses for the period represent employee-related expenses to support product improvements, the development of new technologies and standardized approaches to address new product development opportunities.

 

Selling, General and Administrative Expenses 

 

SG&A expenses decreased $179,827, or 8.1% to $2,049,946 during the three months ended September 30, 2026, compared to $2,229,773 during the three months ended September 30, 2025. The decrease in SG&A for the three-month period was primarily due to decreased severance and a gain on sale of equipment.

 

Other Income (Expense)

 

Interest expense decreased to $30,121 during the three months ended September 30, 2026, compared to $41,775 during the three months ended September 30, 2025, primarily due to lower outstanding principal balances on our term notes. Interest income was $73,577 during the three months ended September 30, 2026, compared to none in the prior year period, primarily reflecting interest earned on higher cash balances following our March 2026 public offering.

 

As a result of the foregoing, net loss decreased to $474,854, or $0.04 per share, during the three months ended September 30, 2026, compared to $1,637,030, or $0.21 per share, during the three months ended September 30, 2025.

 

Liquidity and Capital Resources

 

Based on our current plans and business conditions, management believes that the Company’s available cash and cash equivalents, the cash generated from operations, the availability of our line of credit, and our ability to raise funds in the capital markets will be sufficient to provide for the Company’s working capital and capital expenditure requirements for at least 12 months from the date of this filing. However, our cash on hand and cash generated solely from operations may be insufficient to meet working capital needs for such period and we may be required to raise external financing in the short-term. In addition, our credit arrangements with the Lender require us to maintain minimum liquidity of $2.0 million, and a failure to satisfy this covenant could limit our access to the Revolver or result in an event of default. There can be no assurance that additional financing will be available on acceptable terms, or at all.

 

Net Cash Used in Operating Activities

 

During the three months ended September 30, 2026, net cash used in operating activities totaled $672,145 as compared to $78,227 net cash provided by operating activities during the three months ended September 30, 2025. The decrease in net cash provided by operating activities was primarily due to the decrease in accounts payable and net loss during the three months ended September 30, 2026, partially offset by the decrease in accounts receivable and inventory during such period.

 

 

 

 19 

 

 

Net Cash Used in Investing Activities

 

During the three months ended September 30, 2026, net cash used in investing activities was $48,025, consisting of purchases and disposals of property and equipment. During the three months ended September 30, 2025, net cash used in investing activities was $301,789, consisting of purchases of property and equipment and patent costs.

 

Net Cash Used by Financing Activities

 

During the three months ended September 30, 2026, we made payments of $149,083 on term notes, and paid debt issuance costs of $5,000. During the three months ended September 30, 2025, we made payments of $158,068 on term notes and capital leases.

 

Indebtedness

 

On October 4, 2021, the Company entered into a Loan Agreement with Main Street Bank of Marlborough, Massachusetts (the “Lender”), which provided for a $2,600,000 Term Loan and a $250,000 Revolving Line of Credit Loan Facility (the “Revolver”), which was increased to $500,000 effective May 17, 2022, and $1,250,000 effective June 2, 2023. Borrowings under the Revolver are limited by the borrowing base comprised of a percentage of accounts receivable and inventory and secured by all assets of the Company. Borrowings under the Revolver bear interest payable monthly at the prime lending rate plus 1.5% per annum and shall not be less than 4.75% per annum. Borrowings under the Revolver are due upon demand. There were no borrowings under the Revolver at September 30, 2026.

 

The Company’s Loan Agreement with the Lender contains a minimum annual debt service coverage ratio covenant of 1.2x. As the Company did not meet this annual debt service coverage ratio for the fiscal year ended June 30, 2024, the Company’s Lender agreed to waive compliance with such debt service coverage ratio covenant for the period ended June 30, 2024. In addition to such waiver, the Lender and the Company entered into an amendment dated September 30, 2024 to that certain Term Loan dated October 4, 2021, as amended and that certain Promissory Note dated June 2, 2023 (collectively, the “Notes”) which amendments provided for a six-month period of interest only payments from October 15, 2024 through March 15, 2025 for the Notes. The Company commenced payments of principal and interest under the Notes beginning with the payments due on April 15, 2025, with a new amortization schedule for the remaining term for such Notes through their maturity date. On February 14, 2025, the Lender agreed to waive compliance with the annual debt service coverage ratio covenant for the fiscal year ended June 30, 2025, subject to a $30,000 waiver fee and the completion of an equity raise of at least $4,500,000 by February 24, 2025, which the Company satisfied on February 21, 2025. Any future advances are contingent on the Company achieving a minimum debt service coverage ratio of 1.20x based on quarterly testing, which the Company was not in compliance with as of June 30, 2026. On September 25, 2026, the Lender agreed to waive the Company’s minimum annual debt service coverage ratio covenant for the fiscal year ended June 30, 2026 and modified the Company’s credit arrangements to eliminate the debt service coverage ratio covenant and replace it with a minimum liquidity covenant of $2.0 million, retain the existing term note, and provide the Company access to $750,000 of availability under the Revolver, subject to borrowing-base requirements and a $5,000 waiver fee. The Lender further agreed to expand availability under the Revolver to $1,250,000 upon the Company attaining a debt service coverage ratio of 1.2x. There were no other changes or modifications to the Loan Agreement or the Notes. The Company was in compliance with the minimum liquidity covenant as of September 30, 2026.

  

Capital equipment expenditures and additional patent costs during the three months ended September 30, 2026 and in the same period in the prior year were $118,841 and $523,539, respectively. The prior year amount includes $218,750 of leasehold improvements financed by our landlord.

 

Contractual cash commitments for the fiscal periods subsequent to September 30, 2026, are summarized as follows:

 

   Fiscal 2027   Thereafter   Total 
Minimum operating lease payments  $418,696   $3,088,613   $3,507,309 

 

We have contractual cash commitments related to open purchase orders as of September 30, 2026 of approximately $4,230,000.

  

 

 

 20 

 

 

Off-Balance Sheet Arrangements

 

We currently have no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

As a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.

 

Item 4. Controls and Procedures.

 

Management’s Evaluation of Disclosure Controls and Procedures

 

Our Chief Executive Officer, who is our principal executive officer, and our Chief Financial Officer, who is our principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 30, 2026, to ensure the information we are required to disclose in reports that we file or submit under the Securities Exchange Act of 1934, as amended (i) is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and (ii) is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Our disclosure controls and procedures are intended to provide reasonable assurance that such information is accumulated and communicated to our management.

  

Changes in Internal Control over Financial Reporting

 

There has been no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

 

 

 21 

 

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

Our Company, on occasion, may be involved in legal matters arising in the ordinary course of our business. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business for which we are or could become involved in litigation may have a material adverse effect on our business, financial condition or results of operations. We are not aware of any pending or threatened litigation against us or our officers and directors in their capacity as such that could have a material impact on our operations or finances.

 

Item 1A. Risk Factors.

 

For information regarding factors that could affect our results of operations, financial condition and liquidity, refer to the section entitled “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended June 30, 2026. There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended June 30, 2026 as filed with the SEC on September 28, 2026.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

Not applicable.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

During the period covered by this Quarterly Report on Form 10-Q, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

 

 

 

 22 

 

 

Item 6. Exhibits.

 

Exhibit   Description
     
10.1   Third amendment to the Loan Agreement dated September 25, 2026 by and between Precision Optics Corporation, Inc. and Main Street Bank (included as Exhibit 10.33 to the Registrant’s Annual Report on Form 10-K filed September 28, 2026, and incorporated herein by reference)
     

10.2

 

 
Non-Statutory Stock Option Inducement Grant made effective as of August 18, 2026, by and between Precision Optics Corporation, Inc. and Peter Thier
(incorporated by reference from Exhibit 10.2 to the Form S-8 filed on October 30, 2026)
     
31.1*   Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2*   Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1*   Certification of Officers pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)
     
101.INS*   Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
     
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104*   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

*   Filed herewith (except Exhibit 32.1, which is furnished herewith).

 

 

 

 

 23 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  PRECISION OPTICS CORPORATION, INC.
     
Date: November 16, 2026 By: /s/ Joseph N. Forkey
    Joseph N. Forkey
   

Chief Executive Officer

(Principal Executive Officer)

     
     
Date: November 16, 2026 By: /s/ Wayne M. Coll
    Wayne M. Coll
   

Chief Financial Officer 

(Principal Financial Officer and Principal Accounting Officer)

 

 

 

 

 

 

 

 

 

 

 

 24 

 

Keep reading